glp-1 receptor agonist brands list Market Overview: Agonists and the Obesity Market | Blog Evolution of GLP‐1 Receptor Agonists
Description
Ferulic acid, a phenolic compound present in YM, modestly enhanced GLP-1 secretion in L-cells, whereas its microbial metabolite, dihydroferulic acid, robustly increased GLP-1 secretion

Amycretin is Novo Nordisk's most promising pipeline asset, but Phase 3 confirmation is needed before definitive comparisons can be made

Weve known for a long time that the effects of obesity and related conditions are broader than simply cardiovascular death

The evidence for GLP-1 medications in treating NASH (the more severe form of fatty liver disease) is particularly impressive: Liraglutide achieved histological resolution of steatohepatitis in 39% of cases after 48 weeks, compared to just 9% in placebo groups 20 Patients taking liraglutide had 4.5 times higher likelihood of NASH resolution than those on placebo 20 Semaglutide demonstrated NASH resolution in 59% of participants versus 17% in placebo groups 21 We offer FibroScan technology to measure liver stiffness and fat content, helping us monitor your progress while on GLP-1 therapy

This has implications for people with fatty liver disease who may not have significant obesity

If this trial is successful, we will have the evidence necessary to show the medical community that obesity is a reversible risk factor for atherosclerotic cardiovascular disease and other outcomes, he says
